Abstract
INTRODUCTION
C oats' disease is an exudative retinopathy characterized by light-bulb aneurysms, capillary non-perfusion, progression to exudative retinal detachment and, if untreated, neovascular glaucoma and phthisis bulbi [1] . It is typically a unilateral disease affecting boys and girls in a 3:1 ratio with an average age of onset between 8 and 16y [2] . Despite the average age, new-onset Coats' disease can occur in adults into their eighth decade [3] . Treatment strategies vary and include cryotherapy, laser photocoagulation, external drainage of subretinal fluid, scleral buckling, and pars plana vitrectomy (PPV) [4] . Adjunctive intravitreal injection of corticosteroids [5] [6] and, more recently, anti-vascular endothelial growth factor (VEGF) have also been implemented [7] [8] [9] . Treatment is individualized based on presenting symptoms and progression of disease, yet there have been no randomized, clinical trials to demonstrate efficacy of one modality over another. Moreover, the frequency of complications including vision-limiting vitreoretinal fibrosis, tractional retinal detachment (TRD), neovascular glaucoma and enucleation are unknown, and their relation to individual treatment strategies is especially unclear. Ocular VEGF levels have been shown to be elevated in patients with Coats' disease [10] [11] [12] [13] [14] . This finding prompted investigational use of anti-VEGF agents as both primary and adjuvant therapy with variable success [10, [14] [15] [16] . However, the role of VEGF in Coats' disease is unclear. Although Coats' disease is generally an exudative and not a proliferative retinopathy, occasionally vision may be limited by macular scarring from type 3 choroidal neovascularization (CNV) [17] [18] [19] . If present, this may respond well to anti-VEGF therapy [4] . Since the implementation of anti-VEGF agents for Coats' disease, even in the absence of CNV, certain concerns have surfaced. Ramasubramanian and Shields [20] reported a case series of eight patients with Coats' disease who underwent intravitreal injection of bevacizumab as well as cryotherapy and/or laser-photocoagulation. Eyes of half of these patients developed vitreoretinal fibrosis and 37.5% developed TRD in less than nine months after initial injection [20] . Gaillard et al [21] reported similar findings in their experience with nine Coats' disease children. In the Gaillard study, eyes of five patients went on to develop fibrotic vitreoretinopathy as early as five months after intravitreal anti-VEGF injections. Four out of these five patients also developed cataracts and one progressed to TRD [21] . In 2016, a larger cohort of patients (n=69) treated by this group was described but the relationship between vitreoretinal fibrosis and anti-VEGF agents was unclear in this cohort [22] . Finally, Bhat et al [23] reported findings of three patients that developed TRD after treatment with intravitreal bevacizumab, cryotherapy, and subretinal fluid drainage.
Tractional retinopathy after anti-VEGF treatment is not specific to Coats' disease and has been reported in patients with diabetic retinopathy [24] , retinopathy of prematurity [25] , and familial exudative vitreoretinopathy [26] . With ischemic diseases, such as diabetic retinopathy, a proposed angiofibrotic switch mediated by an imbalance in connective tissue growth factor (CTGF) and VEGF turns on a proliferative response that results in fibrosis and traction (popularly referred to as "crunch") [27] [28] .
However, is the internal milieu of growth factors and cytokines similar in exudative compared to vasoproliferative retinal disease? Furthermore, though complications from intravitreal injections are rare, i.e. subretinal hemorrhage [29] [30] , intraocular inflammation [31] , endophthalmitis [32] , and rhegmatogenous retinal detachment [33] , these can precipitate permanent visual loss, especially in vulnerable eyes.
Despite the recent attention given to anti-VEGF agents, many of the patients reported in the above studies received both cryotherapy and anti-VEGF for more advanced Coats' disease (Stage≥3A). Cryotherapy is a long-standing and effective treatment, especially when large exudative retinal detachment prevents laser photocoagulation. Some fear that extensive cryotherapy leads to epiretinal membrane [34] [35] and vitreoretinal fibrosis [36] [37] , while limited cryoapplication [38] or cryoapplication after air-fluid exchange [39] appears to be safe.
With this in mind, many factors could contribute to vitreoretinal fibrosis with subsequent TRD in Coats' disease including, release of retinal pigment epithelial cells leading to proliferative vitreoretinopathy (PVR) after cryotherapy [36, 40] , an anti-VEGF "crunch" effect [25, 41] , or simply, the natural history of advanced-stage Coats' disease [22, 42] . Accordingly, there are many unknown factors that impact outcomes in Coats' disease.
The goal, therefore, is to understand the potential hazards of each treatment option and to use this information to anticipate adverse outcomes.
We set out to elucidate whether an association exists between treatment modality, including laser photocoagulation, cryotherapy or intravitreal anti-VEGF injections, and occurrence of vitreoretinal fibrosis. Given the absence of prospective data, a pooled data analysis of all published, observational reports was undertaken. There was no time period or language restriction. Institutional review board approval was not required as no identifiable patient information was reviewed. Non-English language articles were excluded unless a translated version was made available by the publisher. Study Selection Author Adeniran JF performed the initial search then Adeniran JF and Duff SM performed the review for eligible eyes and quality of evidence assessment using the GRADE criteria [43] . If there was a disagreement for study quality or eye eligibility, the study was presented to pediatriconcology-trained ophthalmologist Ramasubramanian A for final decision. Data Synthesis and Analysis Individual data were extracted from each paper and included patient age, Stage of Coats' by Shields Classification [44] Binary logistic regression with fibrosis at presentation and treatment type as independent variables was performed in an attempt to determine predictors of TRD. Multivariate analysis was utilized to examine the effect of combination therapy. In all analyses, a two-sided P value <0.05 was considered statistically significant. All presented means are accompanied by their respective standard deviations. RESULTS Four-hundred and eighty-nine articles resulted from the initial search. Three-hundred and fourteen were excluded for reasons including, non-English language (n=87), lack of adequate clinical descriptions (n=135) or were unrelated to or did not significantly discuss Coats' disease (n=92). Following these exclusions, 175 papers detailed treatment and clinical course of 1183 eyes. The first included study was from 1921 [45] and the first report of intravitreal anti-VEGF use was in 2007 [14] . All studies were deemed to be of low to very low quality due to their retrospective nature. Of the 1183 eyes whose clinical courses were reviewed (Table 1) , data for age (mean 13.7y) and length of follow up (mean 45.5mo) was missing for 42.3% of patients (n=502 missing for both age and follow up). Coats' disease staging, based on the Shields Classification [44] , was available in papers published after 2001 (excludes 352 eyes). For the papers after 2001 that had adequate clinical descriptions with wide-field imaging, staging was imposed by the authors if none was explicitly stated. This accounted for staging of 84 eyes. Altogether, ≤Stage 2B accounted for 229 eyes and 530 were ≥Stage 3A.
METHODS
Of the included eyes, 221 received anti-VEGF agents intravitreally. Thirteen were treated with anti-VEGF agents alone, 192 received intravitreal anti-VEGF plus laser, 16 received intravitreal anti-VEGF plus cryotherapy, and 25 received all three treatment modalities. Additionally, 40 eyes received intravitreal steroids alone while 25 received intravitreal steroids in combination with intravitreal anti-VEGF. Since the study was not structured to assess intravitreal steroids independently, these eyes were grouped according to whether also receiving anti-VEGF agent, ablative therapy or observation. Of those reported, most eyes received bevacizumab (n=201), while the rest included ranibizumab (n=47) or pegatinib (n=2). The vast majority of eyes were treated with ablative therapy including cryotherapy and/or laser photocoagulation without anti-VEGF agents (n=765). While we could not distinguish whether laser, cryotherapy or both were used in 175 eyes (ablative therapy), 66 eyes received both, 333 eyes received laser photocoagulation alone, and 191 eyes received cryotherapy alone. Observation occurred in 145 eyes while 36 were initially enucleated. An additional 17 eyes underwent enucleation after laser photocoagulation alone (n=2), cryotherapy alone (n=6), both laser and cryotherapy (n=1), injection plus cryotherapy (n=1) and a period of observation (n=7). Surgery was undertaken in 184 eyes (Table 2) and included vitrectomy alone±external drainage of subretinal fluid (SRF; n=89), scleral buckle (SB)±external drainage of SRF (n=8), vitrectomy and SB±external drainage of SRF (n=26), or external drainage of SRF alone (n=61). Where fibrosis was discussed in more descriptive terms, we classified based on macular or peripheral and epiretinal or subretinal locations. Fibrosis (Table 2) was not an uncommon finding on initial presentation (5.4%; 61/1133). An epiretinal membrane was noted in 23 of these cases (2.0%) and 2 eyes presented with macular holes (0.17%). Additionally, there were 5 (0.44%) cases of TRD on presentation. At final follow up, any form of fibrosis (epiretinal, subretinal; peripheral or macular) occurred in 158 eyes (15.5%), macular holes occurred in an additional 2 eyes (0.35%), and an additional 44 eyes (3.9%) had TRD. One eye that did not initially present with TRD, developed TRD after a period of observation. Eyes with TRD posttreatment and the corresponding treatment given is as shown in Table 2 . Of those receiving intravitreal anti-VEGF and laser, 2.5% (1/192) developed TRD, while 25% (4/16) had cryotherapy and anti-VEGF, 4.5% (3/66) had both laser and cryotherapy, 2.7% (9/333) had laser alone, 4.7% (9/192) had cryotherapy alone, and 20% (5/25) had all 3 treatments. Of the 175 eyes having had "ablative therapy", 12 developed TRD (6.9%). An example of progression of vitreoretinal fibrosis in an unpublished case is presented in the Figure 1 .
As shown in Table 3 Exploring the suggestive association with cryotherapy and TRD further, a secondary analysis was performed on data only since the first reported injection of intravitreal anti-VEGF Cryo+Laser ( Cryotherapy to the temporal quadrant resulted in regression of the telangiectasia but the occurrence of vitreoretinal fibrosis (arrows) with no retinal detachment. Table 3 for Coats' disease [14] . In this subset, cryotherapy showed a significantly higher risk for TRD (OR: 4.9, 95%CI: 2. [18, 46] ; hence, treatment itself likely has an impact on the development or worsening of vitreoretinal traction. If certain triggers for vitreoretinal fibrosis and traction can be identified, TRD may be avoided, ultimately improving outcomes. Our initial purpose for this study was to determine the relationship between anti-VEGF agents and the development of TRD due to earlier reports of such events [20, [22] [23] . However, our pooled data analysis failed to show increased risk of vitreoretinal fibrosis and TRD with use of intravitreal anti-VEGF agents alone. We did, however, find a significant association between the development of TRD in patients that had been treated with cryotherapy in the anti-VEGF era. Additionally, we noted that treatment with laser photocoagulation alone and in combination with intravitreal anti-VEGF therapy decreases the risk of vitreoretinal fibrosis and TRD. Intravitreal anti-VEGF therapy in exudative retinal diseases such as Coats' disease has been reported to decrease subretinal exudates, macular edema, size and number of telangiectatic vessels, improve retinal detachments, and improve visual outcomes. Although there are reports [20] [21] 23] that show a possible association of intravitreal bevacizumab or ranibizumab with TRD in Coats' disease, other authors have attributed the adverse outcomes to the use of aggressive cryotherapy which may elicit proliferative vitreoretinopathy [47] . Daruich et al [22] failed to find a significant difference between those eyes with TRD after cryotherapy compared to laser (P=0.07) in their cohort from years 1989 to 2013. However, the pooled data analysis reported herein shows a possible association between increased TRD in eyes treated with both cryotherapy and anti-VEGF agents. This question, however, would be best studied prospectively. While many advocate use of cryotherapy in presence of exudative RD, there are several reports to suggest that laser is just as effective to treat Coats' disease when the retina is detached [48] . When treatment is targeted to the abnormal vasculature, either green or yellow laser is effectively taken up by hemoglobin in the telangiectatic vessels, precluding the need to target pigment in the retinal pigment epithelium [49] [50] . Five eyes did present with TRD; one was diagnosed based on enucleation specimen in a 3 year old [51] , one in a Coats' plus disease in a 2-year-old [52] , one in a 31-year-old that presented with low vision for an "extended period" of time and had anterior chamber cell and flare [42] , and two reported in a single case series [53] where patients (17 and 18 years old) presented with advanced disease. Similar to all of these cases is the presence of long-standing, advanced disease. Interestingly, higher stage of Coats' disease (≥3A) was not significantly associated with TRD in the current analysis. There are many limitations to this analysis, including lack of standardization of treatment regimens, a wide variety of reporting styles, and missing information such as Coats' disease staging, age, follow up time, and other demographic data. As such, odds ratios were used to estimate associations rather than risk ratios to predict outcomes since this could not be calculated from the available data. Notably, many studies stated that cryotherapy or laser was performed without further details regarding treatment provided and thus were excluded from analysis. Importantly, this accounted for 12 eyes with TRD. We attempted to address the issue of a bias towards use of cryotherapy and worse outcomes in more advance eyes; however, there was no association of Stage ≥3A eyes with TRD. Overall, there is a high risk of reporting bias in any retrospective study and, especially relevant to this study, authors may be reluctant to report or publish cases with significant fibrosis and vitreous traction. Lastly, the questions posed herein would be ideally studied in a prospective, controlled setting. Conclusion When faced with Coats' disease, there are several treatment approaches. While no definitive conclusion may be drawn from a pooled data analysis, we have presented evidence that suggests cryotherapy places patients at a higher risk for post-treatment TRD in this anti-VEGF era. It remains to be seen whether it is the combination of cryotherapy and anti-VEGF that is the culprit. Also evident is that patients presenting with any form of fibrosis are at higher risk to develop progressive vitreoretinal fibrosis and TRD later along with poorer visual acuity [22] . In these cases, one may use cryotherapy and anti-VEGF agents judiciously. Although many questions arise from this analysis, we conclude that treatment of Coats' disease is multi-modal, including various medical and surgical strategies, but that ultimately, the most efficacious regimen remains to be seen. Laser photocoagulation, intravitreal steroids and anti-VEGF agents may represent the safest
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